cirrhosis of liver
cirrhosis of liver
Explore linked clinical trials. Standard reference: MONDO:0005155480 results · Page 1 of 20
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study | Apnea, Atrophy, Body Weight, Dyssomnias, Fibrosis, Insulin Resistance, Neurologic Manifestations, Neuromuscular Manifestations, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Sarcopenia, Signs and Symptoms, Sleep Disorders, Intrinsic, cardiovascular disorder, cirrhosis of liver, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperinsulinism, hypertensive disorder, metabolic disease, muscular atrophy, nervous system disorder, nutritional disorder, obesity disorder, obstructive sleep apnea syndrome, overnutrition, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder, type 2 diabetes mellitus, vascular disorder | Enrolling by invitation | Not stated | 2026-10-09 | NCT07312136 | |
| Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute liver failure, chronic liver failure, cirrhosis of liver, liver disorder, liver failure | Recruiting | Not stated | 2026-10-08 | NCT07585890 | |
| A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction | Digestive System Diseases, Fatigue, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT07304843 | |
| Blood Collection Biorepository for Liver Disease Research | Blood-Borne Infections, Body Weight, DNA Virus Infections, Digestive System Diseases, Fibrosis, Flaviviridae infectious disease, Hepadnaviridae infectious disease, Infections, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pediatric Obesity, RNA Virus Infections, Signs and Symptoms, cirrhosis of liver, fatty liver disease, hepatitis, hepatitis B virus infection, hepatitis C virus infection, infectious disease, liver disorder, metabolic dysfunction-associated steatotic liver disease, nutritional disorder, obesity disorder, overnutrition, viral hepatitis, viral infectious disease | Recruiting | Not stated | 2026-10-08 | NCT03025074 | |
| LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease | Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic liver failure, cirrhosis of liver, liver disorder, liver failure | Recruiting | Not applicable | 2026-10-07 | NCT05998330 | |
| HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease | Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic liver failure, cirrhosis of liver, liver disorder, liver failure | Recruiting | Not applicable | 2026-10-07 | NCT05205954 | |
| Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 2 | 2026-10-07 | NCT05028829 | |
| Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV | Blood-Borne Infections, Digestive System Diseases, Fibrosis, Genital Diseases, HIV infectious disease, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, Urogenital Diseases, cirrhosis of liver, fatty liver disease, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, liver disorder, metabolic dysfunction-associated steatotic liver disease, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Not yet recruiting | Not stated | 2026-10-06 | NCT07861594 | |
| J-LINX: Japan LINerixibat eXtension Study | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis, skin disorder | Not yet recruiting | Phase 3 | 2026-10-06 | NCT07860710 | |
| EUS-Guided Coil and Glue vs Glue Injection for Bleeding Gastric Varices in Cirrhosis | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver | Recruiting | Not applicable | 2026-10-06 | NCT07855913 | |
| Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy | Digestive System Diseases, Disease Attributes, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Rare Diseases, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Not stated | 2026-10-06 | NCT07556913 | |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-10-06 | NCT06051617 | |
| A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Fibrosis, Hemic and Lymphatic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, blood coagulation disease, cirrhosis of liver, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, liver disorder | Recruiting | Phase 2 | 2026-10-05 | NCT07681089 | |
| RTX001 Autologous Engineered Macrophages for Liver Cirrhosis | Brain Diseases, Metabolic, Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Jaundice, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, brain disorder, central nervous system disorder, chronic liver failure, cirrhosis of liver, hepatic encephalopathy, hyperbilirubinemia, liver disorder, liver failure, metabolic disease, nervous system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT06823713 | |
| Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Body Weight, Digestive System Diseases, Fibrosis, Insulin Resistance, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cirrhosis of liver, fatty liver disease, glucose metabolism disease, hyperinsulinism, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 3 | 2026-10-02 | NCT07854782 | |
| Electronic PHES vs Paper-based PHES for Hepatic Encephalopathy | Brain Diseases, Metabolic, Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, central nervous system disorder, cirrhosis of liver, hepatic encephalopathy, liver disorder, liver failure, metabolic disease, nervous system disorder | Not yet recruiting | Not applicable | 2026-10-01 | NCT07852416 | |
| A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy | Brain Diseases, Metabolic, Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, central nervous system disorder, cirrhosis of liver, hepatic encephalopathy, liver disorder, liver failure, metabolic disease, nervous system disorder | Not yet recruiting | Not stated | 2026-10-01 | NCT07612670 | |
| A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06730061 | |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06632444 | |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Active, not recruiting | Not stated | 2026-10-01 | NCT06447168 | |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-10-01 | NCT06016842 | |
| A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 2 | 2026-09-30 | NCT07325526 | |
| Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus | Cholangitis, Sclerosing, Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholangitis, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis, primary sclerosing cholangitis | Not yet recruiting | Phase 2 | 2026-09-28 | NCT07843420 | |
| Molecular Mechanism of Exercise in Cirrhosis | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Not applicable | 2026-09-28 | NCT05982769 | |
| Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | Chemically-Induced Disorders, Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, alcohol-induced disorders, alcohol-related disorders, alcoholic liver cirrhosis, alcoholic liver disease, cirrhosis of liver, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease, substance-related disorder | Recruiting | Phase 2 | 2026-09-28 | NCT05832229 |